Mutual of America Capital Management LLC Has $2.38 Million Position in Insmed Incorporated (NASDAQ:INSM)

Mutual of America Capital Management LLC lowered its holdings in Insmed Incorporated (NASDAQ:INSM) by 20.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 76,928 shares of the biopharmaceutical company’s stock after selling 19,396 shares during the quarter. Mutual of America Capital Management LLC owned about 0.05% of Insmed worth $2,384,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in Insmed in the fourth quarter worth $25,000. Almanack Investment Partners LLC. acquired a new position in Insmed in the third quarter worth $25,000. State of Wyoming acquired a new position in Insmed in the fourth quarter worth $31,000. Quantbot Technologies LP boosted its stake in Insmed by 2,170.4% in the second quarter. Quantbot Technologies LP now owns 2,452 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 2,344 shares in the last quarter. Finally, Vestcor Inc acquired a new position in Insmed in the fourth quarter worth $75,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Guggenheim upped their price target on Insmed from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. StockNews.com raised Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. UBS Group assumed coverage on Insmed in a research note on Tuesday, February 27th. They set a “buy” rating and a $46.00 price target on the stock. Wolfe Research assumed coverage on Insmed in a research note on Thursday, February 15th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $55.00 price target on shares of Insmed in a research note on Monday, April 1st. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $44.64.

Insmed Price Performance

Shares of Insmed stock opened at $24.32 on Friday. Insmed Incorporated has a 1 year low of $17.41 and a 1 year high of $32.00. The business has a 50-day moving average of $27.45 and a two-hundred day moving average of $27.02. The company has a market capitalization of $3.61 billion, a P/E ratio of -4.55 and a beta of 0.92.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The business had revenue of $83.70 million during the quarter, compared to the consensus estimate of $82.15 million. During the same period in the prior year, the business earned ($1.20) EPS. Insmed’s quarterly revenue was up 41.1% on a year-over-year basis. On average, equities analysts anticipate that Insmed Incorporated will post -4.65 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.